Purple Biotech Ltd. Form 6-K Summary
Business Context and Reporting Period
Purple Biotech Ltd., a foreign private issuer based in Rehovot, Israel, filed this Form 6-K on October 28, 2025. The filing serves to announce an upcoming Extraordinary General Meeting of Shareholders scheduled for December 15, 2025.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance notification and does not contain financial statements or performance data.
Material Changes
No material financial changes versus prior periods are reported in this document. The primary event is the scheduling of a shareholder meeting.
Guidance, Outlook, and Corporate Actions
- Shareholder Meeting: An Extraordinary General Meeting will be held on Monday, December 15, 2025, at 4:30 p.m. Israel time.
- Location: 4 Oppenheimer Street, Science Park, Rehovot, Israel.
- Voting Materials: The Notice of Meeting, Proxy Statement, and Voting Slip for ordinary shares are attached as Exhibit 99.1. BNY Mellon will distribute a Voting Instruction Form for American Depositary Share (ADS) holders as Exhibit 99.2.
- Management Commentary: No specific outlook or commentary on business operations is included in this filing.
Key Facts for Investor Verification
- Verify the specific agenda items for the December 15, 2025, Extraordinary General Meeting in the attached Proxy Statement (Exhibit 99.1).
- Confirm the deadline for submitting voting instructions for ADS holders via BNY Mellon.
- Review the attached exhibits for any proposed changes to corporate governance or capital structure.